REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail ViPOR targets tough lymphomas in phase II trial
Disease control Recruiting nowThis phase II trial is testing a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to treatment. The study aims to see how many patien…
Matched conditions: REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo may help more lymphoma patients reach potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs, golcadomide and rituximab, before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to keep the disease in check so more patients can qualify for…
Matched conditions: REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC